Centre intégratif de génomique

Equipe principale | CIG Services communs | Genomics Technologies Facility (GTF) | Group Benton | Group Desvergne | Group Fajas | Group Fankhauser | Group Franken | Group Gambetta | Group Gatfield | Group Hernandez | Group Herr | Group Michalik | Group Reymond | Group Stasiak | Group Thorens | Group Wahli | Group van Leeuwen | Mouse Metabolic Evaluation Facility (MEF) | Protein Analysis Facility (PAF)
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

155 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
The gut microbiota influences skeletal muscle mass and function in mice
Lahiri Shawon, Kim Hyejin, Garcia-Perez Isabel, Reza Musarrat Maisha, Martin Katherine A., Kundu Parag, Cox Laura M., Selkrig Joel, Posma Joram M., Zhang Hongbo et al., 2019/07/24. Science translational medicine, 11 (502) pp. eaan5662. Peer-reviewed.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Fruchart J.C., Santos R.D., Aguilar-Salinas C., Aikawa M., Al Rasadi K., Amarenco P., Barter P.J., Ceska R., Corsini A., Després J.P. et al., 2019/06/04. Cardiovascular Diabetology, 18 (1) p. 71. Peer-reviewed.
The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice.
Caillon A., Duszka K., Wahli W., Rohner-Jeanrenaud F., Altirriba J., 2018/10. Metabolism, 87 pp. 13-17. Peer-reviewed.
Insights into the role of hepatocyte PPARα activity in response to fasting.
Régnier M., Polizzi A., Lippi Y., Fouché E., Michel G., Lukowicz C., Smati S., Marrot A., Lasserre F., Naylies C. et al., 2018/08/15. Molecular and cellular endocrinology, 471 pp. 75-88. Peer-reviewed.
Enteric Microbiota⁻Gut⁻Brain Axis from the Perspective of Nuclear Receptors.
Duszka K., Wahli W., 2018/07/28. International journal of molecular sciences, 19 (8) pp. E2210. Peer-reviewed.
Insights into the Role of PPARβ/δ in NAFLD.
Chen J., Montagner A., Tan N.S., Wahli W., 2018/06/27. International journal of molecular sciences, 19 (7) p. 1893. Peer-reviewed.
Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARβ/δ-Dependent Vasodilator Pathway.
Kirkby N.S., Sampaio W., Etelvino G., Alves D.T., Anders K.L., Temponi R., Shala F., Nair A.S., Ahmetaj-Shala B., Jiao J. et al., 2018/02. Hypertension, 71 (2) pp. 297-305. Peer-reviewed.
Peroxisome Proliferator Activated Receptor Gamma Controls Mature Brown Adipocyte Inducibility through Glycerol Kinase.
Lasar D., Rosenwald M., Kiehlmann E., Balaz M., Tall B., Opitz L., Lidell M.E., Zamboni N., Krznar P., Sun W. et al., 2018/01/16. Cell reports, 22 (3) pp. 760-773. Peer-reviewed.
Complementary intestinal mucosa and microbiota responses to caloric restriction.
Duszka K., Ellero-Simatos S., Ow G.S., Defernez M., Paramalingam E., Tett A., Ying S., König J., Narbad A., Kuznetsov V.A. et al., 2018. Scientific Reports, 8 (1) p. 11338. Peer-reviewed.
PPARγ Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium.
Duszka K., Oresic M., Le May C., König J., Wahli W., 2017/11/28. International journal of molecular sciences, 18 (12) pp. E2559. Peer-reviewed.
Roles of Peroxisome Proliferator-Activated Receptor β/δ in skeletal muscle physiology.
Manickam R., Wahli W., 2017. Biochimie, 136 pp. 42-48. Peer-reviewed.
Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
Tan C.K., Zhuang Y., Wahli W., 2017. Expert Opinion on Therapeutic Targets, 21 (3) pp. 333-348. Peer-reviewed.
High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine.
Tomas J., Mulet C., Saffarian A., Cavin J.B., Ducroc R., Regnault B., Kun Tan C., Duszka K., Burcelin R., Wahli W. et al., 2016/10/04. Proceedings of the National Academy of Sciences of the United States of America, 113 (40) pp. E5934-E5943. Peer-reviewed.
Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency.
Zarei M., Barroso E., Leiva R., Barniol-Xicota M., Pujol E., Escolano C., Vázquez S., Palomer X., Pardo V., González-Rodríguez Á. et al., 2016/10. Diabetes, 65 (10) pp. 3185-3199. Peer-reviewed.
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ.
Tan N.S., Vázquez-Carrera M., Montagner A., Sng M.K., Guillou H., Wahli W., 2016/10. Progress in lipid research, 64 pp. 98-122.
Hepatic Fasting-Induced PPARα Activity Does Not Depend on Essential Fatty Acids.
Polizzi A., Fouché E., Ducheix S., Lasserre F., Marmugi A.P., Mselli-Lakhal L., Loiseau N., Wahli W., Guillou H., Montagner A., 2016/04/24. International journal of molecular sciences, 17 (10) p. 1624. Peer-reviewed.
Hepatic circadian clock oscillators and nuclear receptors integrate microbiome-derived signals.
Montagner A., Korecka A., Polizzi A., Lippi Y., Blum Y., Canlet C., Tremblay-Franco M., Gautier-Stein A., Burcelin R., Yen Y.C. et al., 2016/02/16. Scientific reports, 6 p. 20127. Peer-reviewed.
A trilogy of glucocorticoid receptor actions.
Tan C.K., Wahli W., 2016. Proceedings of the National Academy of Sciences of the United States of America, 113 (5) pp. 1115-1117.
Every day I dream ..." An interview with the Rwandan Health Minister.
Suter P.M., Wahli W., 2016. Swiss Medical Weekly, 146 pp. w14316.
Glucocorticoid receptor-PPARα axis in fetal mouse liver prepares neonates for milk lipid catabolism.
Rando G., Tan C.K., Khaled N., Montagner A., Leuenberger N., Bertrand-Michel J., Paramalingam E., Guillou H., Wahli W., 2016. Elife, 5 pp. e28536. Peer-reviewed.
Intestinal PPARγ signalling is required for sympathetic nervous system activation in response to caloric restriction.
Duszka K., Picard A., Ellero-Simatos S., Chen J., Defernez M., Paramalingam E., Pigram A., Vanoaica L., Canlet C., Parini P. et al., 2016. Scientific Reports, 6 p. 36937. Peer-reviewed.
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A., Polizzi A., Fouché E., Ducheix S., Lippi Y., Lasserre F., Barquissau V., Régnier M., Lukowicz C., Benhamed F. et al., 2016. Gut, 65 (7) pp. 1202-1214. Peer-reviewed.
PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation
Barroso Emma, Rodríguez-Rodríguez Rosalía, Chacón Matilde R., Maymó-Masip Elsa, Ferrer Laura, Salvadó Laia, Salmerón Emilio, Wabistch Martin, Palomer Xavier, Vendrell Joan et al., 2015/05. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1852 (5) pp. 1049-1058. Peer-reviewed.
Authorship in scientific publications: analysis and recommendations.
Scientific Integrity Committee of Swiss Academies of Arts And Sciences, Hess C.W., Brückner C., Kaiser T., Mauron A., Wahli W., Wenzel U.J., Salathé M., 2015. Swiss medical weekly, 145 pp. w14108. Peer-reviewed.
Inactivation of PPARβ/δ adversely affects satellite cells and reduces postnatal myogenesis.
Chandrashekar P., Manickam R., Ge X., Bonala S., McFarlane C., Sharma M., Wahli W., Kambadur R., 2015. American Journal of Physiology. Endocrinology and Metabolism, 309 (2) pp. E122-E131.
Nuclear receptor peroxisome proliferator activated receptor (PPAR) beta/delta in skin wound healing and cancer
Montagner A., Wahli W., Tan N.S., 2015. European Journal of Dermatology, 25 (Suppl 1) pp. 4-11.
PPAR-β/δ activation promotes phospholipid transfer protein expression.
Chehaibi K., Cedó L., Metso J., Palomer X., Santos D., Quesada H., Naceur Slimane M., Wahli W., Julve J., Vázquez-Carrera M. et al., 2015. Biochemical Pharmacology, 94 (2) pp. 101-108.
PPARα is Required for PPARδ action in regulation of body weight and hepatic steatosis in mice.
Garbacz W.G., Huang J.T., Higgins L.G., Wahli W., Palmer C.N., 2015. PPAR Research, 2015 p. 927057.
The coactivator PGC-1α regulates mouse skeletal muscle oxidative metabolism independently of the nuclear receptor PPARβ/δ in sedentary mice fed a regular chow diet
Pérez-Schindler J., Svensson K., Vargas-Fernández E., Santos G., Wahli W., Handschin C., 2015. Diabetologia, 57 (11) pp. 2405-2412. Peer-reviewed.
Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway.
Kundu P., Ling T.W., Korecka A., Li Y., D'Arienzo R., Bunte R.M., Berger T., Arulampalam V., Chambon P., Mak T.W. et al., 2014. PLoS Pathogens, 10 (1) pp. e1003887.
Myostatin augments muscle-specific ring finger protein-1 expression through an NF-kB independent mechanism in SMAD3 null muscle.
Sriram S., Subramanian S., Juvvuna P.K., Ge X., Lokireddy S., McFarlane C.D., Wahli W., Kambadur R., Sharma M., 2014. Molecular Endocrinology, 28 (3) pp. 317-330.
Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer.
Montagner A., Delgado M.B., Tallichet-Blanc C., Chan J.S., Sng M.K., Mottaz H., Degueurce G., Lippi Y., Moret C., Baruchet M. et al., 2014. EMBO Molecular Medicine, 6 (1) pp. 80-98.
The emerging role of Nrf2 in dermatotoxicology.
Tan N.S., Wahli W., 2014. EMBO Molecular Medicine, 6 (4) pp. 431-433.
Contributions of peroxisome proliferator-activated receptor β/δ to skin health and disease
Montagner A., Wahli W., 2013. Biomolecular Concepts, 4 (1) pp. 53-64.
PPARβ Interprets a Chromatin Signature of Pluripotency to Promote Embryonic Differentiation at Gastrulation.
Rotman N., Guex N., Gouranton E., Wahli W., 2013. PLoS One, 8 (12) pp. e83300.
Role of the circadian clock gene Per2 in adaptation to cold temperature.
Chappuis S., Ripperger J.A., Schnell A., Rando G., Jud C., Wahli W., Albrecht U., 2013. Molecular Metabolism, 2 (3) pp. 184-193.
Studying Wound Repair in the Mouse.
Tan N.S., Wahli W., 2013. Current Protocols In Mouse Biology, 3 (3) pp. 171-185. Peer-reviewed.
Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice.
Barroso E., del Valle J., Porquet D., Vieira Santos A.M., Salvadó L., Rodríguez-Rodríguez R., Gutiérrez P., Anglada-Huguet M., Alberch J., Camins A. et al., 2013. Biochimica et Biophysica Acta. Molecular Basis of Disease, 1832 (8) pp. 1241-1248. Peer-reviewed.
The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids.
Ding J., Loizides-Mangold U., Rando G., Zoete V., Michielin O., Reddy J.K., Wahli W., Riezman H., Thorens B., 2013. Cell Reports, 5 (1) pp. 248-258.
GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.
Kostadinova R., Montagner A., Gouranton E., Fleury S., Guillou H., Dombrowicz D., Desreumaux P., Wahli W., 2012. Cell and Bioscience, 2 (1) p. 34.
Lack of Smad3 signaling leads to impaired skeletal muscle regeneration.
Ge X., Vajjala A., McFarlane C., Wahli W., Sharma M., Kambadur R., 2012. American Journal of Physiology. Endocrinology and Metabolism, 303 (1) pp. E90-102.
PPARs at the crossroads of lipid signaling and inflammation.
Wahli W., Michalik L., 2012. Trends in Endocrinology and Metabolism, 23 (7) pp. 351-363.
PPARβ/δ affects pancreatic β cell mass and insulin secretion in mice.
Iglesias J., Barg S., Vallois D., Lahiri S., Roger C., Yessoufou A., Pradevand S., McDonald A., Bonal C., Reimann F. et al., 2012. Journal of Clinical Investigation, 122 (11) pp. 4105-4117.
The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells.
Woldt E., Terrand J., Mlih M., Matz R.L., Bruban V., Coudane F., Foppolo S., El Asmar Z., Chollet M.E., Ninio E. et al., 2012. Nature Communications, 3 (1077) pp. 1-10. Peer-reviewed.
The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Serrano-Marco L., Barroso E., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2012. Diabetologia, 55 (3) pp. 743-751.
Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.
Serrano-Marco L., Rodríguez-Calvo R., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., 2011. Diabetes, 60 (7) pp. 1990-1999.
Beneficial effects of combinatorial micronutrition on body fat and atherosclerosis in mice.
El Kochairi I., Montagner A., Rando G., Lohmann C., Matter C.M., Wahli W., 2011. Cardiovascular Research, 91 (4) pp. 732-741. Peer-reviewed.
Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia.
Kulozik P., Jones A., Mattijssen F., Rose A.J., Reimann A., Strzoda D., Kleinsorg S., Raupp C., Kleinschmidt J., Müller-Decker K. et al., 2011. Cell Metabolism, 13 (4) pp. 389-400.
La nutrigénomique dans votre assiette
Wahli W., Constantin N, 2011. 212, De Boeck.
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats.
Deblon N., Veyrat-Durebex C., Bourgoin L., Caillon A., Bussier A.L., Petrosino S., Piscitelli F., Legros J.J., Geenen V., Foti M. et al., 2011. PLoS One, 6 (9) pp. e25565.
New insights into the role of PPARs.
Montagner A., Rando G., Degueurce G., Leuenberger N., Michalik L., Wahli W., 2011. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 85 (5) pp. 235-243.
PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.
Alvarez-Guardia D., Palomer X., Coll T., Serrano L., Rodríguez-Calvo R., Davidson M.M., Merlos M., El Kochairi I., Michalik L., Wahli W. et al., 2011. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 1811 (2) pp. 59-67. Peer-reviewed.
Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor alpha (PPAR alpha) activity.
Gachon F., Leuenberger N., Claudel T., Gos P., Jouffe C., Fleury Olela F., de Mollerat du Jeu X., Wahli W., Schibler U., 2011. Proceedings of the National Academy of Sciences of the United States of America, 108 (12) pp. 4794-4799. Peer-reviewed.
Sex differences in nuclear receptor-regulated liver metabolic pathways.
Rando G., Wahli W., 2011. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1812 (8) pp. 964-973. Peer-reviewed.
Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet.
Tan C.K., Leuenberger N., Tan M.J., Yan Y.W., Chen Y., Kambadur R., Wahli W., Tan N.S., 2011. Diabetes, 60 (2) pp. 464-476. Peer-reviewed.
Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts.
Ge X., McFarlane C., Vajjala A., Lokireddy S., Ng Z.H., Tan C.K., Tan N.S., Wahli W., Sharma M., Kambadur R., 2011. Cell Research, 21 (11) pp. 1591-1604.
The inhibition of fat cell proliferation by n-3 fatty acids in dietary obese mice.
Hensler M., Bardova K., Jilkova Z.M., Wahli W., Meztger D., Chambon P., Kopecky J., Flachs P., 2011. Lipids in Health and Disease, 10 (1) p. 128.
Peroxisome proliferator-activated receptor β/δ: a master regulator of metabolic pathways in skeletal muscle.
Lahiri S., Wahli W., 2010/12/01. Hormone molecular biology and clinical investigation, 4 (2) pp. 565-573. Peer-reviewed.
Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes.
Vegiopoulos A., Müller-Decker K., Strzoda D., Schmitt I., Chichelnitskiy E., Ostertag A., Berriel Diaz M., Rozman J., Hrabe de Angelis M., Nüsing R.M. et al., 2010. Science, 328 (5982) pp. 1158-1161.
EuroPhenome: a repository for high-throughput mouse phenotyping data.
Morgan H., Beck T., Blake A., Gates H., Adams N., Debouzy G., Leblanc S., Lengger C., Maier H., Melvin D. et al., 2010. Nucleic Acids Research, 38 (Database issue) pp. D577-D585. Peer-reviewed.
Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
Yessoufou A., Wahli W., 2010. Swiss Medical Weekly, 140 pp. w13071.
PPAR modulation of kinase-linked receptor signaling in physiology and disease.
Rotman N., Wahli W., 2010. Physiology, 25 (3) pp. 176-185.
PPARα, a key regulator of hepatic energy homeostasis in health and disease
Leuenberger N., Wahli W., 2010. pp. 305-315 dans Dufour J.F., Clavien P.A. (eds.) Signaling Pathways in Liver Diseases, Springer-Verlag.
A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages.
Demers A., Caron V., Rodrigue-Way A., Wahli W., Ong H., Tremblay A., 2009. Plos One, 4 (11) pp. e7728. Peer-reviewed.
Activation of PPAR delta Regulates Ywhae (Encoding 14-3-3 epsilon Protein), a Gene Required for Ventricular Morphogenesis
Brunelli L., Cieslik K.A., Michalik L., Wahli W., Yost H.J., 2009. pp. E15-E15 dans Basic Cardiovascular Sciences Conference 2009, Circulation Research. Peer-reviewed.
Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets.
Lohmann C., Schäfer N., von Lukowicz T., Sokrates Stein M.A., Borén J., Rütti S., Wahli W., Donath M.Y., Lüscher T.F., Matter C.M., 2009. Atherosclerosis, 207 (2) pp. 360-367. Peer-reviewed.
Fatty acid synthesis and PPARalpha hand in hand.
Rotman N., Wahli W., 2009. Chemistry and Biology, 16 (8) pp. 801-802.
Nutrigenomik, ein neuer Weg zur Gesundheit
Wahli W., Constantin N., 2009. Swiss Medical Forum = Forum Médical Suisse, 9 (11) pp. 224-227.
Nutrigenomik, eine medizinische, soziale und ökonomische Herausforderung
Wahli W., Constantin N., 2009. Swiss Medical Forum = Forum Médical Suisse, 9 (12) pp. 242-245.
Parts of the bothrops moojeni snake venom activated lipid synthesis and PPARA, B, Gamma 2 in transiently transfected sz95 sebocytes
Schagen S. K., Perchuc A.-.M., Voegeli R., Imfeld D., Schreier T., Michalik L., Wahli W., Zouboulis C. C., 2009. Journal der Deutschen Dermatologischen Gesellschaft, 7 pp. 152-153. Peer-reviewed.
Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing.
Chong H.C., Tan M.J., Philippe V., Tan S.H., Tan C.K., Ku C.W., Goh Y.Y., Wahli W., Michalik L., Tan N.S., 2009. Journal of Cell Biology, 184 (6) pp. 817-831. Peer-reviewed.
Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice.
Leuenberger N., Pradervand S., Wahli W., 2009. Journal of Clinical Investigation, 119 (10) pp. 3138-3148.
A gut feeling of the PXR, PPAR and NF-kappaB connection.
Wahli W., 2008. Journal of Internal Medicine, 263 (6) pp. 613-619.
Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.
Rodríguez-Calvo R., Serrano L., Coll T., Moullan N., Sánchez R.M., Merlos M., Palomer X., Laguna J.C., Michalik L., Wahli W. et al., 2008. Diabetes, 57 (8) pp. 2149-2157. Peer-reviewed.
Loss of egg yolk genes in mammals and the origin of lactation and placentation
Brawand D., Wahli W., Kaessmann H., 2008. PLoS Biology, 6 (3) pp. e63. Peer-reviewed.
Nutrition, gestion de l'énergie et surpoids: que font donc nos gènes
Wahli W., 2008. Nouveaux cahiers, 3 pp. 44-78.
Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer.
Jahoor A., Patel R., Bryan A., Do C., Krier J., Watters C., Wahli W., Li G., Williams S.C., Rumbaugh K.P., 2008. Journal of Bacteriology, 190 (13) pp. 4408-4415. Peer-reviewed.
PPAR disruption: Cellular mechanisms and physiological consequences
Rotman N., Haftek-Terreau Z., Luecke S., Feige J., Gelman L., Desvergne B., Wahli W., 2008. CHIMIA, 62 (5) pp. 340-344. Peer-reviewed.
PPAR gamma: ally and foe in bone metabolism.
Wahli W., 2008. Cell Metabolism, 7 (3) pp. 188-190.
PPARs Mediate Lipid Signaling in Inflammation and Cancer.
Michalik L., Wahli W., 2008. PPAR Research, 2008 p. 134059. Peer-reviewed.
Tissue repair and cancer control through PPARs and their coregulators
Michalik L., Wahli W., 2008. pp. 409-440 dans Kumar B., O'Malley R. W. (eds.) Nuclear Receptor Coregulators in Human Diseases chap. 13, World Scientific Publishing.
Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma.
Anghel S.I., Bedu E., Vivier C.D., Descombes P., Desvergne B., Wahli W., 2007. Journal of Biological Chemistry, 282 (41) pp. 29946-29957. Peer-reviewed.
Association with coregulators is the major determinant governing peroxisome proliferator-activated receptor mobility in living cells.
Tudor C., Feige J.N., Pingali H., Lohray V.B., Wahli W., Desvergne B., Engelborghs Y., Gelman L., 2007. Journal of Biological Chemistry, 282 (7) pp. 4417-4426. Peer-reviewed.
Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior.
Michalik L., Zoete V., Krey G., Grosdidier A., Gelman L., Chodanowski P., Feige J.N., Desvergne B., Wahli W., Michielin O., 2007. Journal of Biological Chemistry, 282 (13) pp. 9666-9677. Peer-reviewed.
Fat poetry: a kingdom for PPAR gamma.
Anghel S.I., Wahli W., 2007. Cell Research, 17 (6) pp. 486-511. Peer-reviewed.
Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.
Mandard S., Stienstra R., Escher P., Tan N.S., Kim I., Gonzalez F.J., Wahli W., Desvergne B., Müller M., Kersten S., 2007. Cellular and Molecular Life Sciences, 64 (9) pp. 1145-1157. Peer-reviewed.
Guiding ligands to nuclear receptors.
Michalik L., Wahli W., 2007. Cell, 129 (4) pp. 649-651. Peer-reviewed.
IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.
Berry A., Balard P., Coste A., Olagnier D., Lagane C., Authier H., Benoit-Vical F., Lepert J.C., Séguéla J.P., Magnaval J.F. et al., 2007. European Journal of Immunology, 37 (6) pp. 1642-1652. Peer-reviewed.
Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes.
Indra A.K., Castaneda E., Antal M.C., Jiang M., Messaddeq N., Meng X., Loehr C.V., Gariglio P., Kato S., Wahli W. et al., 2007. Journal of Investigative Dermatology, 127 (5) pp. 1250-1260. Peer-reviewed.
Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease.
Michalik L., Wahli W., 2007. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 1771 (8) pp. 991-998. Peer-reviewed.
Roles of the peroxisome proliferators-activated receptor (PPAR) alpha and beta/delta in skin wound healing
Michalik L., Wahli W., 2007., Proceedings of the Esteve Foundation Symposium 12, held between 4 and 7 October 2006, S'Agaro (Girona), Spain pp. 45-52 dans Werner S. (eds.) Molecular Biology and Pharmacology of tissue Repair, International Congress Series, Elsevier.
Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success.
Wang H., Xie H., Sun X., Tranguch S., Zhang H., Jia X., Wang D., Das S.K., Desvergne B., Wahli W. et al., 2007. Journal of Biological Chemistry, 282 (52) pp. 37770-37782. Peer-reviewed.
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.
Feige J.N., Gelman L., Rossi D., Zoete V., Métivier R., Tudor C., Anghel S.I., Grosdidier A., Lathion C., Engelborghs Y. et al., 2007. Journal of Biological Chemistry, 282 (26) pp. 19152-19166. Peer-reviewed.
The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver.
Stienstra R., Mandard S., Tan N.S., Wahli W., Trautwein C., Richardson T.A., Lichtenauer-Kaligis E., Kersten S., Müller M., 2007. Journal of Hepatology, 46 (5) pp. 869-877. Peer-reviewed.
The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration.
Tan N.S., Icre G., Montagner A., Bordier-ten-Heggeler B., Wahli W., Michalik L., 2007. Molecular and Cellular Biology, 27 (20) pp. 7161-7175. Peer-reviewed.
A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway.
Avallone R., Demers A., Rodrigue-Way A., Bujold K., Harb D., Anghel S., Wahli W., Marleau S., Ong H., Tremblay A., 2006. Molecular Endocrinology, 20 (12) pp. 3165-3178. Peer-reviewed.
Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression.
Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K., DuBois R.N., 2006. Proceedings of the National Academy of Sciences of the United States of America, 103 (50) pp. 19069-19074. Peer-reviewed.
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta.
Nadra K., Anghel S.I., Joye E., Tan N.S., Basu-Modak S., Trono D., Wahli W., Desvergne B., 2006. Molecular and Cellular Biology, 26 (8) pp. 3266-3281. Peer-reviewed.
From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.
Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W., 2006. Progress in Lipid Research, 45 (2) pp. 120-159. Peer-reviewed.
Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis.
Icre G., Wahli W., Michalik L., 2006. Journal of Investigative Dermatology, 11 (1) pp. 30-35. Peer-reviewed.
Integrating nuclear receptor mobility in models of gene regulation.
Gelman L., Feige J.N., Tudor C., Engelborghs Y., Wahli W., Desvergne B., 2006. Nuclear Receptor Signaling, 4 pp. e010. Peer-reviewed.
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S. et al., 2006. Pharmacological Reviews, 58 (4) pp. 726-741. Peer-reviewed.
Involvement of PPAR nuclear receptors in tissue injury and wound repair.
Michalik L., Wahli W., 2006. Journal of Clinical Investigation, 116 (3) pp. 598-606. Peer-reviewed.
Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain.
Knauf C., Rieusset J., Foretz M., Cani P.D., Uldry M., Hosokawa M., Martinez E., Bringart M., Waget A., Kersten S. et al., 2006. Endocrinology, 147 (9) pp. 4067-4078. Peer-reviewed.
PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes.
Schuler M., Ali F., Chambon C., Duteil D., Bornert J.M., Tardivel A., Desvergne B., Wahli W., Chambon P., Metzger D., 2006. Cell Metabolism, 4 (5) pp. 407-414. Peer-reviewed.
Physiological ligands of PPARs in inflammation and lipid homeostasis
Lathion C., Michalik L., Wahli W., 2006. Future Lipidology, 1 (2) pp. 191-201. Peer-reviewed.
PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway.
Varnat F., Heggeler B.B., Grisel P., Boucard N., Corthésy-Theulaz I., Wahli W., Desvergne B., 2006. Gastroenterology, 131 (2) pp. 538-553. Peer-reviewed.
PPARs and colon cancers : A curse or a cure ?
Michalik L., Wahli W., 2006. pp. 145-161 dans Bamba H., Ota S. (eds.) Recent Advances in Gastrointestinal Carcinogenesis, Transworld Research Network.
PPARs in fetal and early postnatal development
Rotman N., Michalik L., Desvergne B., Wahli W., 2006. pp. 33-64 dans Tanejah R. (eds.) Nuclear receptors in development chap. 2, Elsevier.
PPARs: lipid sensors that regulate cell differentiation processes
Varnat F., Michalik L., Desvergne B., Wahli W., 2006. pp. 117-131 dans Brigelius-Flohé R., Joost H.G. (eds.) Nutritional genomics : impact on health and disease chap. 7, Wiley-VCH.
Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock.
Canaple L., Rambaud J., Dkhissi-Benyahya O., Rayet B., Tan N.S., Michalik L., Delaunay F., Wahli W., Laudet V., 2006. Molecular Endocrinology, 20 (8) pp. 1715-1727. Peer-reviewed.
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.
Ali F.Y., Egan K., FitzGerald G.A., Desvergne B., Wahli W., Bishop-Bailey D., Warner T.D., Mitchell J.A., 2006. American Journal of Respiratory Cell and Molecular Biology, 34 (2) pp. 242-246. Peer-reviewed.
The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity.
Mandard S., Zandbergen F., van Straten E., Wahli W., Kuipers F., Müller M., Kersten S., 2006. Journal of Biological Chemistry, 281 (2) pp. 934-944. Peer-reviewed.
Transcriptional regulation of metabolism.
Desvergne B., Michalik L., Wahli W., 2006. Physiological Reviews, 86 (2) pp. 465-514. Peer-reviewed.
Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice.
Skrtic S., Carlsson L., Ljungberg A., Lindén D., Michalik L., Wahli W., Oscarsson J., 2005. Liver International, 25 (1) pp. 33-40. Peer-reviewed.
Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice.
Yang Z.Z., Tschopp O., Di-Poï N., Bruder E., Baudry A., Dümmler B., Wahli W., Hemmings B.A., 2005. Molecular and Cellular Biology, 25 (23) pp. 10407-10418. Peer-reviewed.
EMPReSS: standardised phenotype screens for functional annotation of the mouse genome
Eumorphia_Consortium, Wahli W., Delgado MB., Desvergne B., Michalik L., Bedu E., 2005. Nature Genetics, 37 (11) p. 1155. Peer-reviewed.
Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development.
Di-Poï N., Ng C.Y., Tan N.S., Yang Z., Hemmings B.A., Desvergne B., Michalik L., Wahli W., 2005. Molecular and Cellular Biology, 25 (5) pp. 1696-1712. Peer-reviewed.
Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand.
Feige J.N., Gelman L., Tudor C., Engelborghs Y., Wahli W., Desvergne B., 2005. Journal of Biological Chemistry, 280 (18) pp. 17880-17890. Peer-reviewed.
Functional role of RXRs and PPARgamma in mature adipocytes.
Metzger D., Imai T., Jiang M., Takukawa R., Desvergne B., Wahli W., Chambon P., 2005. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 73 (1) pp. 51-58. Peer-reviewed.
Genetic- or transforming growth factor-beta 1-induced changes in epidermal peroxisome proliferator-activated receptor beta/delta expression dictate wound repair kinetics.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2005. Journal of Biological Chemistry, 280 (18) pp. 18163-18170. Peer-reviewed.
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.
Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., Metzger D., Wahli W., Desvergne B., Naccari G.C. et al., 2005. Journal of Experimental Medicine, 201 (8) pp. 1205-1215. Peer-reviewed.
Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.
Gelman L., Michalik L., Desvergne B., Wahli W., 2005. Current Opinion in Cell Biology, 17 (2) pp. 216-222. Peer-reviewed.
Microsomal triglyceride transfer protein promotes the secretion of Xenopus laevis vitellogenin A1.
Sellers J.A., Hou L., Schoenberg D.R., Batistuzzo de Medeiros S.R., Wahli W., Shelness G.S., 2005. Journal of Biological Chemistry, 280 (14) pp. 13902-13905. Peer-reviewed.
Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2005. Journal of Steroid Biochemistry and Molecular Biology, 93 (2-5) pp. 99-105. Peer-reviewed.
Nutrigenomics and nutrigenetics: the emerging faces of nutrition.
Mutch D.M., Wahli W., Williamson G., 2005. FASEB journal, 19 (12) pp. 1602-1616. Peer-reviewed.
Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation.
Gremlich S., Nolan C., Roduit R., Burcelin R., Peyot M.L., Delghingaro-Augusto V., Desvergne B., Michalik L., Prentki M., Wahli W., 2005. Endocrinology, 146 (1) pp. 375-382. Peer-reviewed.
Peroxisome proliferator activated receptors
Genolet R., Michalik L., Wahli W., 2005. pp. 267-280 dans Dufour J.F., Clavien P.A., Trautwein C., Graf R. (eds.) Signaling pathways in liver diseases, Springer.
Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes.
Planavila A., Rodríguez-Calvo R., Jové M., Michalik L., Wahli W., Laguna J.C., Vázquez-Carrera M., 2005. Cardiovascular Research, 65 (4) pp. 832-841. Peer-reviewed.
Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases.
Bedu E., Wahli W., Desvergne B., 2005. Expert Opinion On Therapeutic Targets, 9 (4) pp. 861-873. Peer-reviewed.
Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure.
Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.P., Heudes D., Wahli W., Desvergne B., Baud L., 2005. Journal of the American Society of Nephrology, 16 (8) pp. 2395-2402. Peer-reviewed.
PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs.
Feige J.N., Sage D., Wahli W., Desvergne B., Gelman L., 2005. Microscopy Research and Technique, 68 (1) pp. 51-58. Peer-reviewed.
PPARs in diseases: control mechanisms of inflammation.
Kostadinova R., Wahli W., Michalik L., 2005. Current Medicinal Chemistry, 12 (25) pp. 2995-3009. Peer-reviewed.
Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha.
Genolet R., Kersten S., Braissant O., Mandard S., Tan N.S., Bucher P., Desvergne B., Michalik L., Wahli W., 2005. Journal of Biological Chemistry, 280 (25) pp. 24143-24152. Peer-reviewed.
Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity.
Debril M.B., Dubuquoy L., Feige J.N., Wahli W., Desvergne B., Auwerx J., Gelman L., 2005. Journal of Molecular Endocrinology, 35 (3) pp. 503-517. Peer-reviewed.
Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing.
Michalik L., Feige J.N., Gelman L., Pedrazzini T., Keller H., Desvergne B., Wahli W., 2005. Molecular Endocrinology, 19 (9) pp. 2335-2348. Peer-reviewed.
The G0/G1 switch gene 2 is a novel PPAR target gene.
Zandbergen F., Mandard S., Escher P., Tan N.S., Patsouris D., Jatkoe T., Rojas-Caro S., Madore S., Wahli W., Tafuri S. et al., 2005. Biochemical Journal, 392 (Pt 2) pp. 313-324. Peer-reviewed.
Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.
Di-Poï N., Desvergne B., Michalik L., Wahli W., 2005. Journal of Biological Chemistry, 280 (46) pp. 38700-38710. Peer-reviewed.
Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action.
Rieusset J., Seydoux J., Anghel S.I., Escher P., Michalik L., Soon Tan N., Metzger D., Chambon P., Wahli W., Desvergne B., 2004. Molecular Endocrinology, 18 (10) pp. 2363-2377. Peer-reviewed.
Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing.
Tan N.S., Michalik L., Di-Poï N., Desvergne B., Wahli W., 2004. Biochemical Society Transactions, 32 (Pt 1) pp. 97-102. Peer-reviewed.
Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression.
Tan N.S., Michalik L., Di-Poï N., Ng C.Y., Mermod N., Roberts A.B., Desvergne B., Wahli W., 2004. EMBO Journal, 23 (21) pp. 4211-4221. Peer-reviewed.
Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.
Di-Poï N., Michalik L., Desvergne B., Wahli W., 2004. Lipids, 39 (11) pp. 1093-1099. Peer-reviewed.
In vivo activation of PPAR target genes by RXR homodimers.
Ijpenberg A., Tan N.S., Gelman L., Kersten S., Seydoux J., Xu J., Metzger D., Canaple L., Chambon P., Wahli W. et al., 2004. EMBO Journal, 23 (10) pp. 2083-2091. Peer-reviewed.
Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha.
Sanguino E., Ramón M., Michalik L., Wahli W., Alegret M., Sánchez R.M., Vázquez-Carrera M., Laguna J.C., 2004. Biochemical Pharmacology, 67 (1) pp. 157-166. Peer-reviewed.
Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse.
Imai T., Takakuwa R., Marchand S., Dentz E., Bornert J.M., Messaddeq N., Wendling O., Mark M., Desvergne B., Wahli W. et al., 2004. Proceedings of the National Academy of Sciences of the United States of America, 101 (13) pp. 4543-4547. Peer-reviewed.
Peroxisome proliferator-activated receptor-beta as a target for wound healing drugs.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2004. Expert Opinion on Therapeutic Targets, 8 (1) pp. 39-48. Peer-reviewed.
Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation.
Mao-Qiang M., Fowler A.J., Schmuth M., Lau P., Chang S., Brown B.E., Moser A.H., Michalik L., Desvergne B., Wahli W. et al., 2004. Journal of Investigative Dermatology, 123 (2) pp. 305-312. Peer-reviewed.
Peroxisome-proliferator-activated receptors and cancers: complex stories.
Michalik L., Desvergne B., Wahli W., 2004. Nature Reviews. Cancer, 4 (1) pp. 61-70. Peer-reviewed.
PPARalpha governs glycerol metabolism.
Patsouris D., Mandard S., Voshol P.J., Escher P., Tan N.S., Havekes L.M., Koenig W., März W., Tafuri S., Wahli W. et al., 2004. Journal of Clinical Investigation, 114 (1) pp. 94-103. Peer-reviewed.
PPARs as drug targets to modulate inflammatory responses?
Genolet R., Wahli W., Michalik L., 2004. Current Drug Targets. Inflammation and Allergy, 3 (4) pp. 361-375. Peer-reviewed.
PPARs in health and disease : central roles in energy homeostasis and tissue repair.
Wahli W, Michalik L, Desvergne B, 2004. BIO, 11 pp. 26-31. Peer-reviewed.
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta.
Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., Das S.K., Dey S.K., DuBois R.N., 2004. Cancer Cell, 6 (3) pp. 285-295. Peer-reviewed.
Regional variations in ABC transporter expression along the mouse intestinal tract.
Mutch D.M., Anderle P., Fiaux M., Mansourian R., Vidal K., Wahli W., Williamson G., Roberts M.A., 2004. Physiological Genomics, 17 (1) pp. 11-20. Peer-reviewed.
The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment.
Mandard S., Zandbergen F., Tan N.S., Escher P., Patsouris D., Koenig W., Kleemann R., Bakker A., Veenman F., Wahli W. et al., 2004. Journal of Biological Chemistry, 279 (33) pp. 34411-34420. Peer-reviewed.
Understanding the coordinated effects of PPARs on lipid metabolism using microarrays.
Kersten S., Escher P., Tafuri S., Wahli W., 2004. pp. 249-263 dans Berger A., Roberts M.A. (eds.) Unraveling Lipid Metabolism with Microarrays chap. 11, CRC Press.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University